T
TiumBio
A drug developer working on treatments for cancer based in South Korean
About TiumBio
TiumBio is a globally recognized research and development company focused on creating innovative treatments for rare and incurable diseases. The company operates in the biopharmaceutical sector, targeting unmet medical needs through the development of new drugs. TiumBio serves a diverse range of clients, including healthcare providers, hospitals, and patients suffering from rare conditions. The company’s business model revolves around extensive research and clinical trials to bring novel therapies to market. Revenue is generated through the commercialization of these drugs, partnerships with other pharmaceutical companies, and licensing agreements. TiumBio's commitment to innovation is evident in its pipeline of promising treatments, such as merigolix for endometriosis and TU2218, a dual inhibitor aimed at enhancing the efficacy of immuno-oncology drugs. The company’s core values emphasize true innovation, excellence, and continuous improvement, driving its mission to improve human health and happiness.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Seongnam-si, South Korea
- Listing
- IPO 2019
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 41.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 2 companies, latest Sep 2021
- Capital deployed
- $97M
- Preferred round
- SERIES E
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2024 | $12M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2023 | $17M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $10M | 0% | −$11M | -103.5% |
| 2025 | $10M | +80.9% | −$11M | -103.5% |
| 2024 | $5.7M | +38.7% | −$737K | -12.9% |
| 2023 | $4.1M | -46.3% | −$10M | -247.1% |
| 2022 | $7.6M | +15896.4% | −$19M | -243.1% |
| 2021 | $48K | -94.6% | −$26M | -53952.2% |
| 2020 | $879K | — | −$10M | -1171.1% |
Growth signals
Latest recorded traffic for TiumBio is 9.8K monthly website visits, up 32.4% over the last three months. TiumBio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Protium ScienceSouth KoreaWith your future in mind
$6.7Mvaluation
SK PlasmaSouth KoreaYou can meet SKPlasma's business and product
$369Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- DNDaol Investment (Formerly KTB Network)
Korea Investment Partners
DSC Investment
Premier Partners- HPHyundai Investment Partners
Korea Development Bank
Kiwoom Securities
IMM Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TiumBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TiumBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.